Cas no 121032-29-9 (Nelarabine)

Nelarabine is a purine nucleoside analog prodrug used primarily as an antineoplastic agent in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It is metabolized intracellularly to arabinosylguanine triphosphate (ara-GTP), which incorporates into DNA, inhibiting DNA synthesis and inducing apoptosis in rapidly dividing cells. Nelarabine demonstrates selective cytotoxicity toward T-cells due to their higher accumulation of ara-GTP compared to B-cells. Its clinical use is supported by its efficacy in refractory or relapsed cases, often as part of combination therapies. The compound is administered intravenously, with dose adjustments recommended for patients exhibiting neurological toxicity, a known side effect.
Nelarabine structure
Nelarabine structure
Product Name:Nelarabine
CAS No:121032-29-9
MF:C11H15N5O5
MW:297.267301797867
MDL:MFCD01723912
CID:63529
PubChem ID:3011155
Update Time:2025-11-27

Nelarabine Chemical and Physical Properties

Names and Identifiers

    • NELARABINE
    • Nelzarabine [USAN]
    • Nelzarabine
    • 9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
    • (2R,3R,4S,5R)-2-(2-Amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
    • 2-Amino-6-methoxypurinribonucleosid
    • 506U78
    • Arranon
    • GW 506U78
    • MAY
    • O6-methyl-guanosine
    • 2-amino-9-β-D-arabinofuranosyl-6-methoxy-9H-purine
    • 9-β-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
    • Atriance
    • GW-506U78
    • 9-(β-D-Arabinofuranosyl)-6-methoxy-9H-purin-2-amine
    • NELARABIN
    • Nelarabine (506U78)
    • Nelarabine (Arranon)
    • 506U
    • 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine
    • (2R,3S,4S,5R)-2-(2-Amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
    • Nelzarabine (USAN)
    • S1213
    • 60158CV180
    • (2R,3S,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
    • DSSTox_RID_81952
    • DSSTox_CID_26842
    • DSSTox_GSID_46842
    • ArranonG
    • 9beta-D-A
    • CAS-121032-29-9
    • (2R,3S,4S,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
    • NSC-755985
    • 2-Amino-6-methoxy-9-(beta-D-arabinofuranosyl)-9H-purine
    • 2-Amino-6-methoxy-9-b-D-arabinofuranosyl-9 H-purine
    • UNII-60158CV180
    • 9H-PURIN-2-AMINE, 9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-
    • AS-47664
    • 2-AMINO-9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-9H-PURINE
    • Attriance
    • Q1216264
    • MLS003915614
    • C11H15N5O5
    • GTPL7090
    • NSC-759876
    • AKOS015920191
    • A935144
    • F15095
    • compound 506U78
    • 121032-29-9
    • NCGC00274059-01
    • NELARABINE [JAN]
    • NELARABINE [WHO-DD]
    • SMR002544682
    • DTXSID6046842
    • NSC755985
    • Nelarabine (JAN/USAN/INN)
    • (2R,3S,4S,5R)-2-(2-azanyl-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
    • SR-01000931847
    • NELARABINE [MART.]
    • BRD-K84466663-001-01-3
    • NSC-686673
    • BP-58633
    • MFCD00871078
    • DTXCID4026842
    • 9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
    • EX-A7779L
    • SCHEMBL18820
    • (2R,3S,4S,5R)-2-(2-amino-6-methoxy-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol
    • 2-Amino-6-methoxypurine arabinoside
    • GW-506U
    • SR-01000931847-3
    • IXOXBSCIXZEQEQ-UHTZMRCNSA-N
    • MLS006010906
    • BCP9000318
    • Arranon (TN)
    • N1144
    • GW506U78
    • 2-Amino-6-methoxy-9-b-D-arabinofuranosyl-9H-purine
    • (2R,3S,4S,5R)-2-(hydroxymethyl)-5-(2-imino-6-methoxy-3,9-dihydro-2H-purin-9-yl)oxolane-3,4-diol
    • Tox21_112714_1
    • Nelarabine [INN]
    • Nelarabine [USAN:INN:BAN]
    • 9-(beta-D-arabinofuranosyl)-6-methoxy-9H-purin-2-amine
    • SW218086-2
    • HY-13701
    • NELARABINE [EMA EPAR]
    • Nelarabine [USAN]
    • NELARABINE [MI]
    • CHEMBL1201112
    • 2-Amino-6-methoxy-9-beta-D-arabinofuranosyl-9H-purine
    • EN300-7361965
    • D05134
    • NCGC00274059-02
    • 9-.BETA.-D-ARABINOFURANOSYL-6-METHOXY-9H-PURIN-2-AMINE
    • 9-?-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
    • 9H-Purin-2-amine, 9-b-D-arabinofuranosyl-6-methoxy-
    • CCG-267441
    • HMS3715I16
    • NELARABINE [ORANGE BOOK]
    • CHEBI:63612
    • A804639
    • MLS004774135
    • 2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
    • DB01280
    • AB01274773_02
    • AKOS015852325
    • Tox21_112714
    • 9-beta-D-arabinofuranosyl-2-amino-6-methoxy-9 H-purine
    • NSC 686673
    • AB01274773-01
    • 9-beta -D-arabinofuranosyl-2-amino-6-methoxy-9H-purine
    • BCPP000392
    • CS-1607
    • NELARABINE [VANDF]
    • NCGC00181098-01
    • 9H-Purin-2-amine, 9beta-D-arabinofuranosyl-6-methyl-
    • BDBM50247985
    • (2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
    • BRD-K84466663-001-05-4
    • Nelarabine
    • MDL： MFCD01723912
    • Inchi： 1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1
    • InChI Key： IXOXBSCIXZEQEQ-UHTZMRCNSA-N
    • SMILES： O1[C@H](CO)[C@H]([C@@H]([C@@H]1N1C=NC2C(=NC(N)=NC1=2)OC)O)O

Computed Properties

  • Exact Mass: 297.10700
  • Monoisotopic Mass: 297.107
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 4
  • Hydrogen Bond Acceptor Count: 9
  • Heavy Atom Count: 21
  • Rotatable Bond Count: 3
  • Complexity: 377
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 4
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -0.7
  • Topological Polar Surface Area: 149

Experimental Properties

  • Color/Form: White solid
  • Density: 1.98
  • Melting Point: 212°C(lit.)
  • Boiling Point: 721°C at 760 mmHg
  • Flash Point: 389.9 °C
  • Refractive Index: 1.829
  • PSA: 148.77000
  • LogP: -1.39020
  • Specific Rotation: +55.9° (c=0.27, DMF)
  • λmax: 286(lit.)
  • Merck: 6442

Nelarabine Security Information

  • Symbol: GHS08
  • Prompt：warning
  • Signal Word：Warning
  • Hazard Statement： H361
  • Warning Statement： P201-P202-P280-P308+P313-P405-P501
  • Hazardous Material transportation number：NONH for all modes of transport
  • RTECS：UO7350000
  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Nelarabine Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
MedChemExpress
HY-13701-10mM*1mLinDMSO
Nelarabine
 121032-29-9 99.88%
10mM*1mLinDMSO
 ￥1377 2023-07-26
MedChemExpress
HY-13701-5mg
Nelarabine
 121032-29-9 99.76%
5mg
 ￥1252 2024-05-25
MedChemExpress
HY-13701-10mg
Nelarabine
 121032-29-9 99.76%
10mg
 ￥2358 2024-05-25
MedChemExpress
HY-13701-50mg
Nelarabine
 121032-29-9 99.76%
50mg
 ￥7149 2024-05-25
MedChemExpress
HY-13701-100mg
Nelarabine
 121032-29-9 99.88%
100mg
 ￥10114 2023-08-31
Fluorochem
093678-250mg
Nelzarabine
 121032-29-9 95%
250mg
 ￡274.00 2022-03-01
Fluorochem
093678-1g
Nelzarabine
 121032-29-9 95%
1g
 ￡717.00 2022-03-01
S e l l e c k ZHONG GUO
S1213-10mM (1mL in DMSO)
Nelarabine
 121032-29-9 99.98%
10mM (1mL in DMSO)
 ￥1624.69 2023-09-16
S e l l e c k ZHONG GUO
S1213-5mg
Nelarabine
 121032-29-9 99.98%
5mg
 ￥1388.59 2023-09-16
S e l l e c k ZHONG GUO
S1213-10mg
Nelarabine
 121032-29-9 99.98%
10mg
 ￥2637.47 2023-09-16

Nelarabine Suppliers

NewCan Biotech Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:121032-29-9)Nelarabine
Order Number:NC8259
Stock Status:
Quantity:10g
Purity:97%
Pricing Information Last Updated:Friday, 18 July 2025 16:17
Price ($):Price inquiry
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:121032-29-9)奈拉濱
Order Number:LE27047763
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 13:02
Price ($):discuss personally
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:121032-29-9)Nelzarabine
Order Number:LY0055
Stock Status:in Stock
Quantity:1KG
Purity:98%standard
Pricing Information Last Updated:Wednesday, 30 July 2025 14:20
Price ($):Inquiry

Nelarabine Spectrogram

13C NMR
13C NMR
1H NMR 300 MHz DMSO
1H NMR

Nelarabine Related Literature

Related Categories

Additional information on Nelarabine

Nelarabine (CAS No. 121032-29-9): A Comprehensive Overview

Nelarabine (CAS No. 121032-29-9) is a purine nucleoside analog that has gained significant attention in the field of oncology due to its efficacy in treating certain types of leukemia and lymphoma. This compound, also known as 5′-O-(1-Ethyl-3,3-dimethylbutyl)guanosine, is a prodrug that is converted to its active form, guanosine triphosphate (GTP), within cells. The mechanism of action of nelarabine involves the inhibition of DNA and RNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cells.

The development of nelarabine has been driven by its unique properties and its ability to overcome resistance mechanisms commonly associated with other nucleoside analogs. Clinical trials have demonstrated its effectiveness in treating T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), particularly in patients who have relapsed or are refractory to standard treatments.

Recent studies have further elucidated the pharmacokinetics and pharmacodynamics of nelarabine. A study published in the Journal of Clinical Oncology in 2021 highlighted the role of nelarabine in combination therapy with other chemotherapeutic agents, such as cytarabine and etoposide. The results showed a significant improvement in overall survival rates and a reduction in the incidence of adverse events compared to monotherapy.

The safety profile of nelarabine has also been extensively evaluated. Common side effects include neurotoxicity, myelosuppression, and gastrointestinal disturbances. However, these side effects are generally manageable with appropriate supportive care and dose adjustments. A recent review article in Blood Advances discussed the management strategies for neurotoxicity associated with nelarabine, emphasizing the importance of early detection and intervention to minimize long-term neurological sequelae.

In addition to its clinical applications, nelarabine has been the subject of numerous preclinical studies aimed at understanding its potential in other cancer types. Research conducted at the National Cancer Institute has shown promising results in preclinical models of solid tumors, including breast cancer and melanoma. These findings suggest that nelarabine may have broader therapeutic applications beyond hematological malignancies.

The synthesis and production of nelarabine have also been optimized to improve its stability and bioavailability. A study published in Organic Process Research & Development described a novel synthetic route that enhances the yield and purity of nelarabine, making it more accessible for large-scale production. This advancement is crucial for ensuring a consistent supply of the drug for clinical use.

In conclusion, Nelarabine (CAS No. 121032-29-9) is a promising therapeutic agent with significant potential in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Its unique mechanism of action, favorable safety profile, and potential for combination therapy make it an important tool in the oncologist's arsenal. Ongoing research continues to explore new applications and optimize its use, further solidifying its position as a valuable treatment option in modern oncology.

121032-29-9 (Nelarabine) Related Products

Recommended suppliers
NewCan Biotech Limited
(CAS:121032-29-9)Nelarabine
NC8259
Purity:97%
Quantity:10g
Price ($):Inquiry
Email
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:121032-29-9)奈拉濱
LE27047763
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email